- Home
- FBIO vs ATYR Comparison
FBIO vs ATYR Comparison
Compare FBIO & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FBIO
- ATYR
- Stock Information
- Founded
- FBIO 2006
- ATYR 2005
- Country
- FBIO United States
- ATYR United States
- Employees
- FBIO N/A
- ATYR N/A
- Industry
- FBIO Biotechnology: Pharmaceutical Preparations
- ATYR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FBIO Health Care
- ATYR Health Care
- Exchange
- FBIO Nasdaq
- ATYR Nasdaq
- Market Cap
- FBIO 88.7M
- ATYR 77.1M
- IPO Year
- FBIO N/A
- ATYR 2015
- Fundamental
- Price
- FBIO $2.75
- ATYR $0.80
- Analyst Decision
- FBIO Strong Buy
- ATYR Buy
- Analyst Count
- FBIO 2
- ATYR 6
- Target Price
- FBIO $16.50
- ATYR $8.75
- AVG Volume (30 Days)
- FBIO 341.4K
- ATYR 3.8M
- Earning Date
- FBIO 11-14-2025
- ATYR 11-06-2025
- Dividend Yield
- FBIO N/A
- ATYR N/A
- EPS Growth
- FBIO N/A
- ATYR N/A
- EPS
- FBIO N/A
- ATYR N/A
- Revenue
- FBIO $62,303,000.00
- ATYR $190,000.00
- Revenue This Year
- FBIO $31.85
- ATYR $420.85
- Revenue Next Year
- FBIO $44.43
- ATYR $1,513.40
- P/E Ratio
- FBIO N/A
- ATYR N/A
- Revenue Growth
- FBIO N/A
- ATYR N/A
- 52 Week Low
- FBIO $1.33
- ATYR $0.64
- 52 Week High
- FBIO $4.20
- ATYR $7.29
- Technical
- Relative Strength Index (RSI)
- FBIO 55.02
- ATYR 42.41
- Support Level
- FBIO $2.40
- ATYR $0.64
- Resistance Level
- FBIO $2.76
- ATYR $0.72
- Average True Range (ATR)
- FBIO 0.16
- ATYR 0.06
- MACD
- FBIO 0.03
- ATYR 0.04
- Stochastic Oscillator
- FBIO 94.59
- ATYR 80.51
About FBIO Fortress Biotech Inc.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, Ximino, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development. It derives the majority of its revenues from Dermatology segment. Its subsidiaries also operate in biotechnology, pharmaceutical, oncology and therapeutics sectors.
About ATYR aTyr Pharma Inc. Common Stock
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.